These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 9857253)
1. [Adjuvant therapy of pemphigus vulgaris and pemphigus foliaceus with intravenous immunoglobulins]. Enk AH; Knop J Hautarzt; 1998 Oct; 49(10):774-6. PubMed ID: 9857253 [TBL] [Abstract][Full Text] [Related]
2. Diagnostic features of pemphigus vulgaris in patients with pemphigus foliaceus: detection of both autoantibodies, long-term follow-up and treatment responses. Sami N; Bhol KC; Ahmed AR Clin Exp Immunol; 2001 Sep; 125(3):492-8. PubMed ID: 11531959 [TBL] [Abstract][Full Text] [Related]
3. Current biologics in treatment of pemphigus foliaceus: a systematic review. Carver CA; Kalesinskas M; Ahmed AR Front Immunol; 2023; 14():1267668. PubMed ID: 37901249 [TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs. Grando SA Int J Dermatol; 2019 Jan; 58(1):114-125. PubMed ID: 30047585 [TBL] [Abstract][Full Text] [Related]
5. Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins. Herzog S; Schmidt E; Goebeler M; Bröcker EB; Zillikens D Acta Derm Venereol; 2004; 84(1):48-52. PubMed ID: 15040478 [TBL] [Abstract][Full Text] [Related]
6. Treatment strategies for pemphigus vulgaris in Japan. Hashimoto T Expert Opin Pharmacother; 2008 Jun; 9(9):1519-30. PubMed ID: 18518782 [TBL] [Abstract][Full Text] [Related]
7. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Bystryn JC; Jiao D Autoimmunity; 2006 Nov; 39(7):601-7. PubMed ID: 17101504 [TBL] [Abstract][Full Text] [Related]
8. Four mild but refractory cases of pemphigus foliaceus successfully treated with intravenous immunoglobulin. Kawakami T; Koga H; Saruta H; Ueda A; Inoue Y; Soma Y; Ishii N; Hashimoto T J Dermatol; 2013 Nov; 40(11):869-73. PubMed ID: 24127870 [TBL] [Abstract][Full Text] [Related]
9. What's new in i.v. immunoglobulin therapy and pemphigus: high-dose i.v. immunoglobulin therapy and its mode of action for treatment of pemphigus. Aoyama Y J Dermatol; 2010 Mar; 37(3):239-45. PubMed ID: 20507387 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-Pem Study): a multicentre randomized controlled trial. van Beek N; Eming R; Reuss A; Zillikens D; Sárdy M; Günther C; Kiritsi D; Benoit S; Beissert S; Gläser R; Gollnick H; Horváth ON; Pfeiffer C; Röcken M; Schauer F; Schreml S; Steinbrink K; Zink A; Schade-Brittinger C; Hertl M; Schmidt E Br J Dermatol; 2024 Apr; 190(5):657-667. PubMed ID: 38133541 [TBL] [Abstract][Full Text] [Related]
11. [Treatment of juvenile pemphigus vulgaris with intravenous immunoglobulins]. Szép Z; Danilla T; Buchvald D Cas Lek Cesk; 2005; 144(10):700-3. PubMed ID: 16279438 [TBL] [Abstract][Full Text] [Related]
12. Diagnosis and treatment of pemphigus. Tsuruta D; Ishii N; Hashimoto T Immunotherapy; 2012 Jul; 4(7):735-45. PubMed ID: 22853759 [TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. Ahmed AR J Am Acad Dermatol; 2001 Nov; 45(5):679-90. PubMed ID: 11606916 [TBL] [Abstract][Full Text] [Related]
14. [Pemphigus: a review]. Joly P; Sin C Ann Dermatol Venereol; 2011 Mar; 138(3):182-200. PubMed ID: 21397148 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic features of pemphigus vulgaris in patients with bullous pemphigoid. Molecular analysis of autoantibody profile. Sami N; Bhol KC; Beutner EH; Plunkett RW; Leiferman KM; Ahmed AR Dermatology; 2002; 204(2):108-17. PubMed ID: 11937735 [TBL] [Abstract][Full Text] [Related]
16. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris. Engineer L; Bhol KC; Ahmed AR J Am Acad Dermatol; 2000 Dec; 43(6):1049-57. PubMed ID: 11100022 [TBL] [Abstract][Full Text] [Related]
17. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients. Kim MR; Kim HC; Kim SC Dermatology; 2011; 223(2):182-8. PubMed ID: 22025028 [TBL] [Abstract][Full Text] [Related]
18. Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Shimanovich I; Herzog S; Schmidt E; Opitz A; Klinker E; Bröcker EB; Goebeler M; Zillikens D Clin Exp Dermatol; 2006 Nov; 31(6):768-74. PubMed ID: 16824051 [TBL] [Abstract][Full Text] [Related]
19. Pemphigus vulgaris. Combined treatment with intravenous corticosteroid pulse therapy, plasmapheresis, and azathioprine. Fine JD; Appell ML; Green LK; Sams WM Arch Dermatol; 1988 Feb; 124(2):236-9. PubMed ID: 3277542 [TBL] [Abstract][Full Text] [Related]
20. [Prolonged complete clinical remission in patients with severe pemphigus vulgaris after cycles of intravenous cyclophosphamide]. España Alonso A; Panizo C; Fernández S; Marquina M; Pretel M; Aguado L; Sánchez-Ibarrola A Actas Dermosifiliogr; 2009 Mar; 100(2):113-20. PubMed ID: 19445875 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]